pmedpharmФармация и фармакологияPharmacy & Pharmacology2307-92662413-2241Pyatigorsk Medical and Pharmaceutical Institute - branch of Volgograd State Medical Univer10.19163/2307-9266-2021-9-2-130-138pmedpharm-830Research ArticleФАРМАКОЛОГИЯ И КЛИНИЧЕСКАЯ ФАРМАКОЛОГИЯPHARMACOLOGY AND CLINICAL PHARMACOLOGYОЦЕНКА СОЦИАЛЬНО-ЭКОНОМИЧЕСКОГО БРЕМЕНИ ХРОНИЧЕСКОЙ ОБСТРУКТИВНОЙ БОЛЕЗНИ ЛЕГКИХ ЗА 5-ЛЕТНИЙ ПЕРИОД – РЕГИОНАЛЬНЫЙ АСПЕКТЕSTIMATION OF SOCIO-ECONOMIC BURDEN OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE FOR A 5-YEAR PERIOD: A REGIONAL ASPECThttps://orcid.org/0000-0001-7169-3586ОрловаЕ. А.OrlovaE. A.

кандидат медицинских наук, доцент, заведующая кафедрой фармакологии

Candidate of Sciences (Medicine), Associate Professor, the Head of the Department of Pharmacology

eorlova56@mail.ruhttps://orcid.org/0000-0002-3129-2443УмероваА. Р.UmerovaA. R.

доктор медицинских наук, доцент, заведующая кафедрой клинической фармакологии; руководитель территориального органа Росздравнадзора по Астраханской области 

Doctor of Sciences (Medicine), Associate Professor, Head of the Department of Clinical Pharmacology

adelya_umerova@mail.ruhttps://orcid.org/0000-0003-1561-0592ДорфманИ. П.DorfmanI. P.

кандидат медицинских наук, доцент, доцент кафедры клинической фармакологии

Candidate of Sciences (Medicine), Associate Professor, Associate Professor of the Department of Clinical Pharmacology

inna1977@inbox.ruhttps://orcid.org/0000-0002-8995-6572ОрловМ. А.OrlovM. A.

доктор медицинских наук, профессор, заведующий кафедрой медицинской реабилитации

Doctor of Sciences (Medicine), Professor, the Head of the Department of Medical Rehabilitation

orlovdoc56@gmail.comhttps://orcid.org/0000-0001-7374-2660АбдуллаевМ. А.AbdullaevM. A.

аспирант кафедры фармакологии

post-graduate student of the Department of Pharmacology

abdullaev-musalitdin@mail.ruФедеральное государственное бюджетное образовательное учреждение высшего образования «Астраханский государственный медицинский университет» Министерства здравоохранения Российской федерации 414000, Россия, г. Астрахань, ул. Бакинская, д. 121РоссияAstrakhan State Medical University 121, Bakinskaya Str., Astrakhan, Russia, 414000Russian Federation1. Федеральное государственное бюджетное образовательное учреждение высшего образования «Астраханский государственный медицинский университет» Министерства здравоохранения Российской федерации 414000, Россия, г. Астрахань, ул. Бакинская, д. 121 2. Территориальный орган Федеральной службы по надзору в сфере здравоохранения по Астраханской области 414040, Россия, г. Астрахань, ул. Коммунистическая, 27Россия1. Astrakhan State Medical University 121, Bakinskaya Str., Astrakhan, Russia, 414000 2. Territorial body of Federal State Surveillance Service in Healthcare for Astrakhan Region 27, Kommunisticheskaya Str., Astrakhan, Russia 414040Russian Federation20212107202192130138Copyright © Орлова Е.А., Умерова А.Р., Дорфман И.П., Орлов М.А., Абдуллаев М.А., 20212021Орлова Е.А., Умерова А.Р., Дорфман И.П., Орлов М.А., Абдуллаев М.А.Orlova E.A., Umerova A.R., Dorfman I.P., Orlov M.A., Abdullaev M.A.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.pharmpharm.ru/jour/article/view/830Цель

Цель. Оценка экономического ущерба от ХОБЛ, включая прямые медицинские и немедицинские затраты и непрямые затраты, связанные с преждевременной смертью лиц трудоспособного возраста.

Материалы и методы

Материалы и методы. Впервые проведена оценка экономического бремени ХОБЛ в Астраханской области (АО) с использованием клинико-экономического анализа «стоимость болезни». В исследовании учитывались прямые медицинские затраты на стационарное, амбулаторное лечение, скорую и неотложную медицинскую помощь, а также прямые немедицинские затраты, связанные с выплатами пособий по инвалидности. Непрямые затраты определялись как экономические потери от не произведенной продукции вследствие преждевременной смерти в экономически активном возрасте.

Результаты

Результаты. Экономическое бремя ХОБЛ в АО за период с 2015 по 2019 гг. суммарно составило 757,11 млн. рублей, что эквивалентно 0,03 % валового регионального продукта за пятилетний период исследования. Прямые медицинские и немедицинские затраты суммарно составили 178,02 млн. рублей. В структуре прямых медицинских затрат расходы на стационарную, а также скорую и неотложную медицинскую помощь за период исследования увеличились на 92,5% и 45,5% соответственно. В то время как затраты на амбулаторную помощь уменьшились на 31,9%, прирост прямых немедицинских затрат, связанных с выплатами пособий по инвалидности, вырос на 5,1% к 2019 г. Непрямые потери составили 579,09 млн. рублей.

Заключение

Заключение. В структуре основного ущерба преобладают непрямые потери в экономике, связанные с преждевременной смертью населения экономически активного возраста. В структуре прямых медицинских затрат превалировали затраты на стационарную помощь. Данные исследования свидетельствуют о необходимости продолжения более углубленного анализа экономического бремени ХОБЛ, а также оптимизации лечения и профилактики развития обострений данного заболевания.

The aim of the study was to estimate the economic damage by COPD, including direct medical and non-medical costs and indirect costs associated with premature deaths of working-age individuals.

Materials and methods

Materials and methods. First, estimation of the economic COPD burden in Astrakhan region (AR) was carried out using the clinical and economic analysis of the "cost of illness" (COI). Direct medical costs of inpatient, outpatient, ambulance and emergency medical care, as well as direct non-medical costs associated with the disability benefits payments, were taken into account. Indirect costs were defined as economic losses from undelivered products due to premature deaths of working-age individuals.

Results

Results. From 2015 to 2019, the economic COPD burden in AR amounted to 757.11 million rubles in total, which is equivalent to 0.03% of the gross regional product covering a five-year period of the study. Direct medical and non-medical costs totaled 178.02 million rubles. In the structure of direct medical expenses, expenses for inpatient, as well as ambulance and emergency medical care during the study period, increased by 92.5% and 45.5%, respectively. While the costs for the outpatient care decreased by 31.9%, the increase in direct non-medical costs associated with the disability benefits payments, increased by 5.1% (2019). Indirect losses amounted to 579.09 million rubles.

Conclusion

Conclusion. The structure of the main damage is dominated by indirect losses in the economy associated with premature deaths of working-age individuals. In the structure of direct medical costs, inpatient care costs prevailed. These studies indicate the need to continue an advanced analysis of the economic burden of COPD, as well as to optimize the treatment and prevention of the exacerbations development of this disease.

хроническая обструктивная болезнь легкихэкономическое бремяпрямые медицинские затратыпрямые немедицинские затратынепрямые затратыАстраханская областьChronic Obstructive Pulmonary Diseaseeconomic burdendirect medical costsdirect non-medical costsindirect costsAstrakhan regionДанное исследование не имело финансовой поддержки от сторонних организаций.ReferencesIheanacho I., Zhang S., King D., Rizzo M., Ismaila A.S. Economic Burden of Chronic Obstructive Pulmonary Disease (COPD): A Systematic Literature Review // Int J Chron Obstruct Pulmon Dis. – 2020. – Vol.15. – P.439-460. DOI: 10.2147/COPD.S234942.Iheanacho I, Zhang S, King D, Rizzo M, Ismaila AS. Economic Burden of Chronic Obstructive Pulmonary Disease (COPD): A Systematic Literature Review. Int J Chron Obstruct Pulmon Dis. 2020;15:439-460. DOI: 10.2147/COPD.S234942.Кузьмичев Б.Ю., Воронина Л.П., Тарасочкина Д.С., Полунина О.С., Прокофьева Т.В., Липницкая Е.А., Полунина Е. А. Гипергомоцистеинемия как фактор риска осложненного течения инфаркта миокарда на фоне хронической обструктивной болезни легких // Астраханский медицинский журнал. – 2019. – Т. 14, № 3. – С. 79-87. DOI: 10.17021/2019.14.3.79.87Kuzmichev B.Yu., Voronina L.P., Tarasochkina D.S., Polunina O.S., Prokofieva T.V., Lipnitskaya E.A., Polunina E.A. Hyperhomocysteinemia as a risk factor for a complicated course of myocardial infarction against the background of the chronic obstructive pulmonary disease. Astrakhan medical journal. 2019; 14(3): 79-87. DOI: 10.17021/2019.14.3.79.87. RussianBlanco I., Diego I., Bueno P., Fernández E., Casas-Maldonado F., Esquinas C., Soriano J.B., Miravitlles M. Geographical distribution of COPD prevalence in Europe, estimated by an inverse distance weighting interpolation technique // International journal of chronic obstructive pulmonary disease. – 2017. – Vol.13. – p.57–67. DOI: 10.2147/COPD.S150853Blanco I, Diego I, Bueno P, Fernández E, Casas-Maldonado F, Esquinas C, Soriano JB, Miravitlles M. Geographical distribution of COPD prevalence in Europe, estimated by an inverse distance weighting interpolation technique. International journal of chronic obstructive pulmonary disease. 2017;13:57–67. DOI: 10.2147/COPD.S150853Chuchalin A.G., Khaltaev N., Antonov N.S., Galkin D.V., Manakov L.G., Antonini P., Murphy M., Solodovnikov A.G., Bousquet J., Pereira M.H., Demko I.V. Chronic respiratory diseases and risk factors in 12 regions of the Russian Federation // International journal of chronic obstructive pulmonary disease. – 2014. – Vol.9. – P.963–974. DOI: 10.2147/COPD.S67283Chuchalin AG, Khaltaev N, Antonov NS, Galkin DV, Manakov LG, Antonini P, Murphy M, Solodovnikov AG, Bousquet J, Pereira MH, Demko IV. Chronic respiratory diseases and risk factors in 12 regions of the Russian Federation. International journal of chronic obstructive pulmonary disease. 2014;9:963–974. DOI: 10.2147/COPD.S67283ВОЗ (Всемирная организация здравоохранения). 10 ведущих причин смерти в мире. 2019. [Электронный ресурс]. URL: https://www.who.int/ru/news-room/fact-sheets/detail/the-top-10-causes-of-death [Дата обращения 13.01.2021].WHO; World Health Organization. The top 10 causes of death. 2019. [Date of access 13 Jan 2021]. Available from: https://www.who.int/ru/news-room/fact-sheets/detail/the-top-10-causes-of-death.Li X., Zhou Y., Chen S., Zheng J., Zhong N., Ran P. Early intervention with tiotropium in Chinese patients with GOLD stages I—II chronic obstructive pulmonary disease (Tie-COPD) study protocol for a multicentre, double-blinded, randomised, controlled trial // Br. Med. J. Open. – 2014. – Vol.4, No.2. - e003991. DOI:10.1136/bmjopen-2013-003991Li X, Zhou Y, Chen S, Zheng J, Zhong N, Ran P. Early intervention with tiotropium in Chinese patients with GOLD stages I—II chronic obstructive pulmonary disease (Tie-COPD) study protocol for a multicentre, double-blinded, randomised, controlled trial. Br. Med. J. Open. 2014;4(2):e003991.doi:10.1136/bmjopen-2013-003991Srivastava K., Thakur D., Sharma S., Punekar Y.S. Systematic review of humanistic and economic burden of symptomatic chronic obstructive pulmonary disease // Pharmaco Economics. – 2015. – Vol.33, No.5. – P.467–488. DOI: 10. 1007/s40273-015-0252-4.Srivastava K, Thakur D, Sharma S, Punekar YS. Systematic review of humanistic and economic burden of symptomatic chronic obstructive pulmonary disease. Pharmaco Economics. 2015;33(5):467–488. DOI: 10. 1007/s40273-015-0252-4.Mannino D.M., Higuchi K., Yu T.C., Zhou H., Li Y., Tian H., Suh K. Economic burden of chronic obstructive pulmonary disease by presence of comorbidities // Chest. – 2015. – Vol.148. – P.138–50. DOI: 10.1378/chest.14-2434.Mannino DM, Higuchi K, Yu TC, Zhou H, Li Y, Tian H, Suh K. Economic burden of chronic obstructive pulmonary disease by presence of comorbidities. Chest 2015;148:138–50. DOI: 10.1378/chest.14-2434.European Respiratory Society. Lung health in Europe: a better understanding of lung disease and respiratory care in Europe facts & figures. 2014. [Электронный ресурс]. URL: https:// www.ersnet.org/. [Дата обращения 13.01.2021].European Respiratory Society. Lung health in Europe: a better understanding of lung disease and respiratory care in Europe facts & figures, 2014. [Date of access 13 Jan 2021]. Available from: https://www.ersnet.org/.Крысанов И.С. Анализ стоимости хронической обструктивной болезни лёгких в Российской Федерации // Качественная клиническая практика. – 2014. - № 2. – С. 51-57.Krysanov I.S. Analysis the cost of chronic obstructive pulmonary disease in Russian Federation. Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice. 2014;(2):51-56. RussianКонцевая А.В., Муканеева Д.К., Баланова Ю.А., Худяков М.Б., Драпкина О.М. Экономический ущерб от болезней органов дыхания и хронической обструктивной болезни легких в Российской Федерации в 2016 году // Пульмонология. – 2019. – Т. 29, №2. – С. 159–166. DOI: 10.18093/0869-0189-2019-29-2-159-166.Kontsevaya A.V., Mukaneyeva D.K., Balanova Yu.A., Khudyakov M.B., Drapkina O.M. Economic burden of respiratory diseases and chronic obstructive pulmonary disease in Russian Federation, 2016. Pulmonologiya. 2019;29(2):159-166. DOI:10.18093/0869-0189-2019-29-2-159-166 RussianEhteshami-Afshar S., FitzGerald J.M., Doyle-Waters M.M., Sadatsafavi M. The global economic burden of asthma and chronic obstructive pulmonary disease // Int J Tuberc Lung Dis. – 2016. – Vol.20, No.1. – P.11-23. DOI: 10.5588/ijtld.15.0472.Ehteshami-Afshar S, FitzGerald JM, Doyle-Waters MM, Sadatsafavi M. The global economic burden of asthma and chronic obstructive pulmonary disease. Int J Tuberc Lung Dis. 2016 Jan;20(1):11-23. DOI: 10.5588/ijtld.15.0472.Anees Ur. Rehman, Ahmad Hassali M.A., Muhammad S.A., Shah S., Abbas S., Hyder Ali I.A.B., Salman A. The economic burden of chronic obstructive pulmonary disease (COPD) in the USA, Europe, and Asia: results from a systematic review of the literature // Expert Rev Pharmacoecon Outcomes Res. – 2020. – Vol.20, No.6. – P.661-672. DOI: 10.1080/14737167.2020.1678385.Anees Ur Rehman, Ahmad Hassali MA, Muhammad SA, Shah S, Abbas S, Hyder Ali IAB, Salman A. The economic burden of chronic obstructive pulmonary disease (COPD) in the USA, Europe, and Asia: results from a systematic review of the literature. Expert Rev Pharmacoecon Outcomes Res. 2020 Dec;20(6):661-672. doi: 10.1080/14737167.2020.1678385.Stafyla E., Geitona M., Kerenidi T., Economou A., Daniil Z., Gourgoulianis K.I. The annual direct costs of stable COPD in Greece // Int J Chron Obstruct Pulmon Dis. – 2018. – Vol.13. – P.309-315. DOI: 10.2147/COPD.S148051.Stafyla E, Geitona M, Kerenidi T, Economou A, Daniil Z, Gourgoulianis KI. The annual direct costs of stable COPD in Greece. Int J Chron Obstruct Pulmon Dis. 2018 Jan 15;13:309-315. DOI: 10.2147/COPD.S148051.Viegi G., Maio S., Fasola S., Baldacci S. Global Burden of Chronic Respiratory Diseases // J Aerosol Med Pulm Drug Deliv. – 2020. – Vol.33, No.4. – P.171-177. DOI: 10.1089/jamp.2019.1576.Viegi G, Maio S, Fasola S, Baldacci S. Global Burden of Chronic Respiratory Diseases. J Aerosol Med Pulm Drug Deliv. 2020 Aug;33(4):171-177. DOI: 10.1089/jamp.2019.1576.Dhamane A.D., Witt E.A., Su J. Associations between COPD severity and work productivity, health-related quality of life, and health care resource use: a cross-sectional analysis of national survey data // J Occup Environ Med. – 2016. – Vol.58, No.6. – P.191–197. DOI: 10.1097/JOM.0000000000000735Dhamane AD, Witt EA, Su J. Associations between COPD severity and work productivity, health-related quality of life, and health care resource use: a cross-sectional analysis of national survey data. J Occup Environ Med. 2016;58(6):e191–e197. DOI: 10.1097/JOM.0000000000000735Vitacca M., Bianchi L., Bazza A., Clini E.M. Advanced COPD patients under home mechanical ventilation and/or long term oxygen therapy: italian healthcare costs // Monaldi Arch Chest Dis. – 2011. – Vol.75, No.4. – P.207–214. DOI: 10.4081/monaldi.2011.208Vitacca M, Bianchi L, Bazza A, Clini EM. Advanced COPD patients under home mechanical ventilation and/or long term oxygen therapy: italian healthcare costs. Monaldi Arch Chest Dis. 2011;75(4):207–214. DOI: 10.4081/monaldi.2011.208Punekar Y.S., Wurst K., Shukla A. Resource use and costs up to two years post diagnosis among newly diagnosed COPD patients in the UK primary care setting: a retrospective cohort study // COPD. – 2015. – Vol.12, No.3. – P.267–275. DOI: 10.3109/15412555.2014.933953Punekar YS, Wurst K, Shukla A. Resource use and costs up to two years post diagnosis among newly diagnosed COPD patients in the UK primary care setting: a retrospective cohort study. COPD. 2015;12(3):267–275. DOI: 10.3109/15412555.2014.933953Guarascio A.J., Ray S.M., Finch C.K., Self T.H. The clinical and economic burden of chronic obstructive pulmonary disease in the USA. Clinicoecon // Outcomes Res. – 2013. – Vol.5. – P.235–245. DOI: 10.2147/CEOR.S34321.Guarascio AJ, Ray SM, Finch CK, Self TH. The clinical and economic burden of chronic obstructive pulmonary disease in the USA. Clinicoecon. Outcomes Res. 2013;5:235–245. DOI: 10.2147/CEOR.S34321.Ford E.S., Murphy L.B., Khavjou O., Giles W.H., Holt J.B., Croft J.B. Total and state-specific medical and absenteeism costs of COPD among adults aged ≥ 18 years in the United States for 2010 and projections through 2020 // Chest. – 2015. – Vol.147, No.1. – P.31-45. DOI: 10.1378/chest.14-0972.Ford ES, Murphy LB, Khavjou O, Giles WH, Holt JB, Croft JB. Total and state-specific medical and absenteeism costs of COPD among adults aged ≥ 18 years in the United States for 2010 and projections through 2020. Chest. 2015 Jan;147(1):31-45. DOI: 10.1378/chest.14-0972.Trueman D., Woodcock F., Hancock E. Estimating the economic burden of respiratory illness in the UK. British Lung Foundation. 2017. [Электронный ресурс]. URL: https://www.blf.org.uk/policy/economic-burden. [Дата обращения 13.01.2021].Trueman D, Woodcock F, Hancock E. Estimating the economic burden of respiratory illness in the UK. British Lung Foundation; 2017. [Date of access 13 Jan 2021]. Available from: https://www.blf.org.uk/policy/economic-burden.Foo J., Landis S.H., Maskell J., Oh Y.M., Van Der Molen T., Han M.K., Punekar Y. Continuing to Confront COPD International Patient Survey: economic impact of COPD in 12 countries // PLoS One. – 2016. – Vol.11, No.4. - e0152618. DOI:10.1371/journal. pone.0152618.Foo J, Landis SH, Maskell J, Oh YM, Van Der Molen T, Han MK, Punekar Y. Continuing to Confront COPD International Patient Survey: economic impact of COPD in 12 countries. PLoS One. 2016;11(4):e0152618. DOI:10.1371/journal. pone.0152618.Wacker M.E., Jörres R.A., Schulz H., Heinrich J., Karrasch S., Karch A., Koch A., Peters A., Leidl R., Vogelmeier C., Holle R.; COSYCONET-Consortium. Direct and indirect costs of COPD and its comorbidities: Results from the German COSYCONET study // Respir Med. – 2016. – Vol.111. – P.39-46. DOI: 10.1016/j.rmed.2015.12.001.Wacker ME, Jörres RA, Schulz H, Heinrich J, Karrasch S, Karch A, Koch A, Peters A, Leidl R, Vogelmeier C, Holle R; COSYCONET-Consortium. Direct and indirect costs of COPD and its comorbidities: Results from the German COSYCONET study. Respir Med. 2016 Feb;111:39-46. DOI: 10.1016/j.rmed.2015.12.001.Patel J.G., Nagar S.P., Dalal A.A. Indirect costs in chronic obstructive pulmonary disease: a review of the economic burden on employers and individuals in the United States // Int J Chron Obstruct Pulmon Dis. – 2014. – Vol.9. – P.289-300. DOI: 10.2147/COPD.S57157.Patel JG, Nagar SP, Dalal AA. Indirect costs in chronic obstructive pulmonary disease: a review of the economic burden on employers and individuals in the United States. Int J Chron Obstruct Pulmon Dis. 2014 Mar 19;9:289-300. DOI: 10.2147/COPD.S57157.

The authors declare that there are no conflicts of interest present.